Inventor · disambiguated record
Steven W. Andrews
Also filed as: ANDREWS STEVEN · ANDREWS STEVEN W · ANDREWS STEVEN WADE
97 granted patents·30 pending applications·2,697 citations·filing 1992–2023
99Inventor score
Top patents by PatentIndex Score
127 records- 0199US9676783B2Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compoundsARRAY BIOPHARMA INC·Filed 2015·Granted Jun 13, 2017·23 cites·83 claims
- 0299US9127013B2Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compoundsARRAY BIOPHARMA INC·Filed 2015·Granted Sep 8, 2015·47 cites·30 claims
- 0399US8865698B2Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compoundsARRAY BIOPHARMA INC·Filed 2013·Granted Oct 21, 2014·45 cites·33 claims
- 0499US6403649B1Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agentsALLERGAN SALES INC·Filed 2000·Granted Jun 11, 2002·272 cites·3 claims
- 0598US10174028B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·14 cites·29 claims
- 0698US10174027B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Jan 8, 2019·17 cites·30 claims
- 0798US10138243B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Nov 27, 2018·14 cites·29 claims
- 0898US10112942B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 30, 2018·29 cites·30 claims
- 0998US9493476B2Macrocyclic compounds as trk kinase inhibitorsARRAY BIOPHARMA INC·Filed 2014·Granted Nov 15, 2016·46 cites·14 claims
- 1098US9447104B2Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compoundsARRAY BIOPHARMA INC·Filed 2014·Granted Sep 20, 2016·21 cites·92 claims
- 1198US8017655B2Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agentsALLERGAN INC·Filed 2008·Granted Sep 13, 2011·24 cites·6 claims
- 1298US7491794B2Macrocyclic compounds as inhibitors of viral replicationINTERMUNE INC·Filed 2005·Granted Feb 17, 2009·147 cites·1 claims
- 1398US5688819ACyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agentsALLERGAN INC·Filed 1996·Granted Nov 18, 1997·309 cites·20 claims
- 1497US10953005B1Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2020·Granted Mar 23, 2021·4 cites·16 claims
- 1597US10137124B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Nov 27, 2018·12 cites·29 claims
- 1697US10047097B2Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compoundsARRAY BIOPHARMA INC·Filed 2018·Granted Aug 14, 2018·9 cites·22 claims
- 1797US10023570B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Jul 17, 2018·14 cites·103 claims
- 1897US10005783B2Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compoundsARRAY BIOPHARMA INC·Filed 2017·Granted Jun 26, 2018·10 cites·140 claims
- 1997US9902741B2Macrocyclic compounds as TRK kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Feb 27, 2018·22 cites·15 claims
- 2097US9840519B2Macrocyclic compounds as TRK kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Dec 12, 2017·21 cites·5 claims
- 2197US9750744B2Macrocyclic compounds as Trk kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Sep 5, 2017·21 cites·29 claims
- 2297US9718822B2Macrocyclic compounds as Trk kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Aug 1, 2017·22 cites·15 claims
- 2397US8791123B2Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitorsALLEN SHELLEY·Filed 2010·Granted Jul 29, 2014·94 cites·61 claims
- 2497US8513263B2Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitorsHAAS JULIA·Filed 2009·Granted Aug 20, 2013·110 cites·30 claims
- 2597US6765012B23-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitorsALLERGAN INC·Filed 2002·Granted Jul 20, 2004·137 cites·20 claims
- 2697US5352708ANon-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agentsALLERGAN INC·Filed 1992·Granted Oct 4, 1994·195 cites·8 claims
- 2796US10208024B22-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinasesARRAY BIOPHARMA INC·Filed 2016·Granted Feb 19, 2019·32 cites·27 claims
- 2896US10172851B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·8 cites·29 claims
- 2996US9796724B2Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 24, 2017·16 cites·30 claims
- 3096US9782415B2Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 10, 2017·19 cites·30 claims
- 3196US6747025B1Kinase inhibitors for the treatment of diseaseALLERGAN INC·Filed 2003·Granted Jun 8, 2004·57 cites·9 claims
- 3295US9796723B2Method of treatment using substituted imidazo[1,2b]pyridazine compoundsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 24, 2017·15 cites·30 claims
- 3395US9795611B2Method of treatment using substituted imidazo[1,2b]pyridazine compoundsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 24, 2017·15 cites·30 claims
- 3495US9682979B2Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitorsARRAY BIOPHARMA INC·Filed 2014·Granted Jun 20, 2017·27 cites·43 claims
- 3595US8933084B2Macrocyclic compounds as Trk kinase inhibitorsANDREWS STEVEN WADE·Filed 2011·Granted Jan 13, 2015·113 cites·52 claims
- 3695US8119592B2Compounds and methods for inhibiting hepatitis C viral replicationBEIGELMAN LEONID·Filed 2006·Granted Feb 21, 2012·54 cites·13 claims
- 3794US10555944B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Feb 11, 2020·10 cites·12 claims
- 3894US8299021B2Macrocyclic inhibitors of hepatitis C virus replicationBLATT LAWRENCE M·Filed 2012·Granted Oct 30, 2012·47 cites·2 claims
- 3994US5607978ANon-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agentsALLERGAN INC·Filed 1995·Granted Mar 4, 1997·117 cites·8 claims
- 4093US10647730B2Macrocyclic compounds as TRK kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted May 12, 2020·4 cites·15 claims
- 4193US10011604B2Method of treatment using substituted imidazo[1,2b]pyridazine compoundsARRAY BIOPHARMA INC·Filed 2015·Granted Jul 3, 2018·9 cites·18 claims
- 4293US7829665B2Macrocyclic inhibitors of hepatitis C virus replicationINTERMUNE INC·Filed 2006·Granted Nov 9, 2010·27 cites·29 claims
- 4393US6541504B1(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitorsALLERGAN SALES LLC·Filed 2002·Granted Apr 1, 2003·61 cites·18 claims
- 4492US7015220B23-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitorsALLERGAN INC·Filed 2004·Granted Mar 21, 2006·37 cites·45 claims
- 4592US7005444B23-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitorsALLERGAN INC·Filed 2002·Granted Feb 28, 2006·43 cites·16 claims
- 4692US6559173B13-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitorsALLERGAN INC·Filed 2002·Granted May 6, 2003·38 cites·10 claims
- 4791US10907215B2Point mutations in TRK inhibitor-resistant cancer and methods relating to the sameLOXO ONCOLOGY INC·Filed 2018·Granted Feb 2, 2021·3 cites·27 claims
- 4891US10688100B2Macrocylic compounds as ROS1 kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jun 23, 2020·3 cites·3 claims
- 4991US10172845B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·4 cites·29 claims
- 5091US6699863B1Kinase inhibitors for the treatment of diseaseALLERGAN INC·Filed 2002·Granted Mar 2, 2004·43 cites·7 claims
Showing the top 50 of 127 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Steven W. Andrews files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →